The Experts below are selected from a list of 259875 Experts worldwide ranked by ideXlab platform
Dave J Adams - One of the best experts on this subject based on the ideXlab platform.
-
Multicomponent Low Molecular Weight gelators
Chemical Communications, 2015Co-Authors: Jaclyn Raeburn, Dave J AdamsAbstract:Low Molecular Weight gelators (LMWG) self-assemble in solution into one-dimensional objects such as fibres or tapes. The entanglement of these fibres or tapes results in the formation of a network and a gel. In general, LMWG are investigated as single component systems. However, there are significant potential opportunities from mixed LMWG systems, which are rarely investigated. Here, we discuss the potential of multicomponent systems, and critically discuss the challenges.
-
Low Molecular Weight gelator dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
-
Low Molecular Weight gelator–dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
Lin Chen - One of the best experts on this subject based on the ideXlab platform.
-
Low Molecular Weight gelator dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
-
Low Molecular Weight gelator–dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
Walther Jungwirth - One of the best experts on this subject based on the ideXlab platform.
-
Low-Molecular-Weight heparin and postoperative bleeding in rhytidectomy.
Plastic and Reconstructive Surgery, 2008Co-Authors: Peter Durnig, Walther JungwirthAbstract:BACKGROUND Postoperative bleeding and hematoma are unwanted complications, especially for face lifts, where the rate of hematoma is reported to be high. The authors investigated the rate of complications. As expected, the major adverse event was postoperative bleeding, requiring surgical evacuation of hematoma in 5.6 percent of cases. Plastic surgeons in Europe are currently under pressure to use Low-Molecular-Weight heparin in every face lift patient because of the guidelines of the European Consensus Conference for Prophylaxis of Thromboembolism. METHODS Over a period of 1.5 years, a total of 126 patients took part in a retrospective, controlled trial on postoperative bleeding, with two comparative groups. Thirty-seven patients had received Low-Molecular-Weight heparin; in 89 patients, no heparin thrombosis prophylaxis was used. The standard for each of the 126 rhytidectomy patients operated on was as folLows: one surgeon, use of compression stockings, analgosedation, and mobilization of the patient on the day of operation. RESULTS The authors observed a 16.2 percent rate of postoperative bleeding in the Low-Molecular-Weight heparin-group, compared with 1.1 percent in the group where no Low-Molecular-Weight heparin was used. This was highly significant, especially when the Fisher's exact test was applied (p < 0.003). In 89 patients, when using compression stockings, analgosedation, and mobilization of the patient on the day of operation, the authors observed had no symptomatic thrombosis or pulmonary embolism if not using Low-Molecular-Weight heparin. CONCLUSIONS The authors conclude that the rate of postoperative bleeding in face lifts under the use of Low-Molecular-Weight heparin is higher than generally expected. As no symptomatic thrombosis or embolism without using Low-Molecular-Weight heparin occurred, it seems that the use of Low-Molecular-Weight heparin in face lifts is not categorically necessary in Low-risk patients.
-
Low-Molecular-Weight heparin and postoperative bleeding in rhytidectomy.
Plastic and Reconstructive Surgery, 2006Co-Authors: Peter Durnig, Walther JungwirthAbstract:Postoperative bleeding and hematoma are unwanted complications, especially for face lifts, where the rate of hematoma is reported to be high. The authors investigated the rate of complications. As expected, the major adverse event was postoperative bleeding, requiring surgical evacuation of hematoma in 5.6 percent of cases. Plastic surgeons in Europe are currently under pressure to use Low-Molecular-Weight heparin in every face lift patient because of the guidelines of the European Consensus Conference for Prophylaxis of Thromboembolism. Over a period of 1.5 years, a total of 126 patients took part in a retrospective, controlled trial on postoperative bleeding, with two comparative groups. Thirty-seven patients had received Low-Molecular-Weight heparin; in 89 patients, no heparin thrombosis prophylaxis was used. The standard for each of the 126 rhytidectomy patients operated on was as folLows: one surgeon, use of compression stockings, analgosedation, and mobilization of the patient on the day of operation. The authors observed a 16.2 percent rate of postoperative bleeding in the Low-Molecular-Weight heparin-group, compared with 1.1 percent in the group where no Low-Molecular-Weight heparin was used. This was highly significant, especially when the Fisher's exact test was applied (p < 0.003). In 89 patients, when using compression stockings, analgosedation, and mobilization of the patient on the day of operation, the authors observed had no symptomatic thrombosis or pulmonary embolism if not using Low-Molecular-Weight heparin. The authors conclude that the rate of postoperative bleeding in face lifts under the use of Low-Molecular-Weight heparin is higher than generally expected. As no symptomatic thrombosis or embolism without using Low-Molecular-Weight heparin occurred, it seems that the use of Low-Molecular-Weight heparin in face lifts is not categorically necessary in Low-risk patients.
-
Low-Molecular-Weight heparin and postoperative bleeding in rhytidectomy. Discussion
Plastic and Reconstructive Surgery, 2006Co-Authors: Peter Durnig, Walther Jungwirth, James M. StuzinAbstract:Background: Postoperative bleeding and hematoma are unwanted complications, especially for face lifts, where the rate of hematoma is reported to be high. The authors investigated the rate of complications. As expected, the major adverse event was postoperative bleeding, requiring surgical evacuation of hematoma in 5.6 percent of cases. Plastic surgeons in Europe are currently under pressure to use Low-Molecular-Weight heparin in every face lift patient because of the guidelines of the European Consensus Conference for Prophylaxis of Thromboembolism. Methods: Over a period of 1.5 years, a total of 126 patients took part in a retrospective, controlled trial on postoperative bleeding, with two comparative groups. Thirty-seven patients had received Low-Molecular-Weight heparin; in 89 patients, no heparin thrombosis prophylaxis was used. The standard for each of the 126 rhytidectomy patients operated on was as folLows: one surgeon, use of compression stockings, analgosedation, and mobilization of the patient on the day of operation. Results: The authors observed a 16.2 percent rate of postoperative bleeding in the Low-Molecular-Weight heparin-group, compared with 1.1 percent in the group where no Low-Molecular-Weight heparin was used. This was highly significant, especially when the Fisher's exact test was applied (p < 0.003). In 89 patients, when using compression stockings, analgosedation, and mobilization of the patient on the day of operation, the authors observed had no symptomatic thrombosis or pulmonary embolism if not using Low-Molecular-Weight heparin. Conclusions: The authors conclude that the rate of postoperative bleeding in face lifts under the use of Low-Molecular-Weight heparin is higher than generally expected. As no symptomatic thrombosis or embolism without using Low-Molecular-Weight heparin occurred, it seems that the use of Low-Molecular-Weight heparin in face lifts is not categorically necessary in Low-risk patients.
Marc Verstraete - One of the best experts on this subject based on the ideXlab platform.
-
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
Drugs, 1990Co-Authors: Marc VerstraeteAbstract:Standard unfractionated heparin is a mixture of mucopolysaccharide chains of various length that may vary from 5000 to 30000 daltons. Heparin is only effective as an anticoagulant in the presence of a plasma protein termed antithrombin III, with which it forms a complex. High- and Low-affinity heparin are 2 types that readily bind or do not bind, respectively, to antithrombin III. The pharmacokinetics of unfractionated heparin are compatible with a model based on the combination of a saturable and a linear mechanism. The primary indication for intravenous infusion of conventional heparin is to prevent extension of an established arterial, venous or intracardiac thrombus. The average requirement is 400 U/kg/24h. Subcutaneous administration of 5000U of concentrated unfractionated heparin, administered every 8 or 12 hours, is effective and safe in the prevention of postoperative venous thrombosis and pulmonary embolism in patients at medium thrombotic risk. Adequate prophylaxis is also obtained in patients at high thrombotic risk if 5000U of heparin combined with 0.5mg dihydroergotamine is given subcutaneously 3 times daily, or by monitoring the 3 subcutaneous doses of heparin in order to maintain an adjusted activated partial thromboplastin time (APTT) of around 50 to 70 seconds. Low Molecular Weight heparins have been produced by a variety of techniques and their Molecular Weights range from 3000 to 9000 daltons. These preparations have a ratio of anti-factor Xa activity to anti-factor IIa activity of about 4, while the ratio for unfractionated heparin is 1. After intravenous administration of Low Molecular Weight heparin, the half-life of the anti-factor Xa activity is considerably longer than for unfractionated heparin, while the anti-factor IIa half-lives are similar. In contrast to unfractionated heparin, Low Molecular Weight heparin is completely absorbed after subcutaneous administration and its biological half-life is almost twice as long. In spite of certain differences with regard to the ratio between factor Xa and IIa inhibition, the various Low Molecular Weight preparations show a rather similar absorption pattern. The bioavailability of all Low Molecular Weight heparin fractions is substantially higher than that of unfractionated heparin, which renders their use more simple. Low Molecular Weight heparins less readily enhance platelet aggregation although there is no evidence that Low Molecular Weight heparins are less antigenic or that they do not interact with platelet IgGFc receptor. A Lower bleeding incidence for equivalent antithrombotic efficacy of fractionated heparins when compared to unfractionated heparins has yet to be established in humans. For prophylaxis of postoperative deep vein thrombosis, one daily subcutaneous injection of Low Molecular Weight heparin results in satisfactory protection with almost no risk of bleeding. For the treatment of deep venous thrombosis, 2 daily injections of Low Molecular Weight heparin are necessary. The presently recommended doses of each Low Molecular Weight heparin differ and are less well established than for standard unfractionated heparin. After intravenous injection of 100U unfractionated heparin full neutralisation is obtained with 1 mg protamine; the activities of Low Molecular Weight heparins can be neutralised to a lesser extent. Several of the adverse effects of unfractionated heparin, such as thrombocytopenia and osteoporosis, have also been observed with Low Molecular Weight heparins, but activation of lipoprotein lipase seems to occur to a minor extent with the latter.
Steven Revel - One of the best experts on this subject based on the ideXlab platform.
-
Low Molecular Weight gelator dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
-
Low Molecular Weight gelator–dextran composites
Chemical Communications, 2010Co-Authors: Lin Chen, Steven Revel, Kyle L Morris, David G Spiller, Louise C Serpell, Dave J AdamsAbstract:Incorporation of dextran into a hydrogel formed using a Low Molecular Weight dipeptide-conjugate gelator results in controlled modification of the material properties.
